NERVE STIMULATION FOR TREATMENT OF DISEASES AND DISORDERS

• US 20180021580A1
• Filed: 08/15/2017
• Published: 01/25/2018
• Est. Priority Date: 02/20/2015
• Status: Active Grant

• Current Assignee: The Feinstein Institutes For Medical Research
• Original Assignee: The Feinstein Institute for Medical Research (Northwell Health, Inc.)
• Inventors: Tracey, Kevin J., Chavan, Sangeeta S.
• Granted Patent: US 10,507,327 B2
• Time in Patent Office: Days
• CPC Class Codes: A61N 1/36002 Cancer treatment, e.g. tumour
• CPC Class Codes: A61N 1/36007 of urogenital or gastrointestinal organs, e.g. for incontinence control
• CPC Class Codes: A61N 1/36053 adapted for vagal stimulation A61N1/36114 takes precedence
• CPC Class Codes: A61N 1/36071 Pain
• CPC Class Codes: A61N 1/36135 using physiological parameters

Abstract

Methods are disclosed for treating a subject having a disease or disorder comprising stimulating a nerve of the subject with a corrective stimulus pattern derived from a disease-specific, condition-specific, endogenous mediator-specific or pharmacologic agent-specific neurogram in an amount and manner effective to treat the disease or disorder.

Claims

1. A method for treating a subject having a disease or disorder comprising stimulating a nerve of the subject with a corrective stimulus pattern derived from a disease-specific, condition-specific, endogenous mediator-specific or pharmacologic agent-specific neurogram in an amount and manner effective to treat the disease or disorder.

2. The method of claim 1, wherein the disease or disorder is one or more of inflammation, type 1 diabetes, type 2 diabetes, metabolic syndrome, insulin resistance, glucose intolerance, hyperglycemia, hypoglycemia, trauma, bleeding, hemorrhagic shock, ischemia-reperfusion injury, nausea, vomiting, cancer, prostate cancer, arthritis, rheumatoid arthritis, sepsis, endotoxemia, colitis, pancreatitis, inflammatory bowel disease, Crohn'"'"'s Disease, fever, anorexia, pain, swelling, kidney failure, liver disease, hypothyroidism, a host response to infection, an immune response, and a disease or disorder in which it is desirable to increase the activity or level of a cytokine.

3. The method of claim 1, wherein the disease-specific, condition-specific, endogenous mediator-specific or pharmacologic agent-specific neurogram is obtained using an animal model of the disease or disorder, or from a human patient.

5. The method of claim 1, wherein the neurogram is obtained in response to administration of a cytokine or administration of glucagon, glucose or insulin to the subject.

8. The method of claim 1, wherein the disease-specific, condition-specific, endogenous mediator-specific or pharmacologic agent-specific neurogram is obtained from the vagus nerve, splenic nerve, splanchnic nerve, sciatic nerve, or a nerve to a specific organ or portion of an organ.

10. The method of claim 1, wherein corrective stimulus pattern is applied to the vagus nerve, splenic nerve, splanchnic nerve, sciatic nerve, or a nerve to a specific organ or portion of an organ.

11. The method of claim 1, wherein a cytokine-specific neurogram is used to induce a cytokine-specific physiological effect.

12. The method of claim 1 for controlling blood glucose levels in a subject, the method comprising stimulating a cervical vagus nerve of the subject with a corrective stimulus pattern derived from a hypoglycemic- or hyperglycemic-specific neurogram recorded from a vagus nerve in an amount and manner effective to control blood glucose levels in a subject.

13. The method of claim 12 for decreasing blood glucose levels in a subject comprising stimulating a cervical vagus nerve of the subject with a corrective stimulus pattern derived from a hypoglycemic-specific, insulin-specific or cortisol-specific neurogram recorded from a vagus nerve in an amount and manner effective to decrease blood glucose levels in a subject.

14. The method of claim 13, wherein the cervical vagus nerve is stimulated with a corrective stimulus pattern derived from a hypoglycemic-specific neurogram recorded from a vagus nerve.

15. The method of claim 13, wherein the cervical vagus nerve is stimulated with a corrective stimulus pattern derived from an insulin-specific neurogram recorded from a vagus nerve.

17. The method of claim 15, wherein the decrease in blood glucose levels is mediated by vagal afferent signaling.

22. The method of claim 13, wherein the subject receiving vagus nerve stimulation has one or more of diabetes mellitus type 1, diabetes mellitus type 2, metabolic syndrome, glucose intolerance, insulin resistance and hyperglycemia.

24. The method of claim 12 for increasing blood glucose levels in a subject comprising stimulating a cervical vagus nerve of the subject with a corrective stimulus pattern derived from a hperglycemia-specific or glucose-specific neurogram recorded from a vagus nerve in an amount and manner effective to increase blood glucose levels in a subject.

28. The method of claim 24, wherein the subject receiving vagus nerve stimulation has one or more of hypoglycemia, kidney failure, liver disease and hypothyroidism.

29. The method of claim 1 for treating a subject having inflammation, the method comprising stimulating a cervical vagus nerve of the subject with a corrective stimulus pattern derived from an anti-inflammatory cytokine-specific or cortisol-specific or dexamethasone-specific neurogram recorded from a vagus nerve in an amount and manner effective to treat inflammation in a subject.

41. The method of claim 29, wherein stimulation of the cervical vagus nerve with a corrective stimulus pattern derived from a cortisol-specific neurogram decreases blood glucose levels in the subject.

42. The method of claim 1, wherein the corrective stimulus pattern is applied to the vagus nerve and wherein physiologic effects of the corrective stimulus pattern are mediated by vagal nerve afferents.

43. The method of claim 1, wherein the neurogram is obtained from an animal model or a human patient.

4. (canceled)

6-7. -7. (canceled)

9. (canceled)

16. (canceled)

18-21. -21. (canceled)

23. (canceled)

25-27. -27. (canceled)

30-40. -40. (canceled)

44. (canceled)

45. A method for generating a corrective stimulus for the treatment of a disease or condition, comprising the steps of:

providing a disease-specific, condition-specific, endogenous mediator-specific or pharmacologic agent-specific neurogram, and

generating a corrective neural stimulus based therefrom.

46-50. -50. (canceled)